Jeffrey W. Johannes
AstraZeneca (United Kingdom)(GB)AstraZeneca (Brazil)(BR)Molecular Oncology (United States)(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Toxin Mechanisms and Immunotoxins, Phytochemicals and Medicinal Plants, Radical Photochemical Reactions, Catalytic C–H Functionalization Methods
Most-Cited Works
- → Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia(2018)480 cited
- → Photoredox Mediated Nickel Catalyzed Cross-Coupling of Thiols With Aryl and Heteroaryl Iodides via Thiyl Radicals(2016)442 cited
- → Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis(2020)238 cited
- → Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross‐Coupling of Primary Aryl Amines with Aryl Halides(2016)209 cited
- → Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper(2022)161 cited
- → Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs(2021)131 cited